AVEO Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AVEO Pharmaceuticals, Inc.
AbbVie pays $130m up front with up to $870m in earnout potential for UCB spinout focused on SV2A modulators. BioNTech gets rights to preclinical TCR candidates for solid tumors from Medigene.
FDA’s use of advisory committees is at a historic low – as are the prospects of sponsors getting a positive outcome. Is it COVID? Or a more fundamental shift in how FDA uses its panels?
CDER hit a high mark with 27 first-in-class approvals in the 50 novel agents cleared in 2021.
The number of new drugs that launched in 2021 was on par with recent high trends, but launch trajectories generally underwhelmed commercially – except for COVID-19 vaccines.
- Drug Discovery Tools
Drug Discovery Tools
- Other Names / Subsidiaries
- AVEO Oncology